| Literature DB >> 35784957 |
Wardah Aslam1, Maryam Habib2, Saeeda Aziz3.
Abstract
Introduction Lymphomas are a heterogeneous group of disorders that arise primarily from lymphoid tissue and are categorized based on histological features and immunophenotypes. The distribution and frequency of different types of lymphoma vary in different parts of the world. This study aimed to document the frequency and clinicopathological characteristics of various types of lymphoma in our population to understand the ever-increasing burden of disease and formulate the optimal management and prevention plans. Materials and methods This study was conducted at Nuclear Medicine, Oncology and Radiotherapy Institute (NORI) from August 2015 to March 2022. A total of 300 cases of lymphoma that were diagnosed and treated at NORI were included in the study. We measured the frequency of different lymphomas and patient age, sex, and stage IV presentation at the time of diagnosis. IBM SPSS Statistics for Windows, Version 23.0 (Armonk, NY: IBM Corp.) was used to analyze the data. Results Three hundred patients with lymphoma were included in the study. There were more non-Hodgkin's lymphoma (NHL) cases (n=224; 74.6%) than Hodgkin's lymphoma (HL) cases (n=76; 25.3%). T-cell NHL was seen in 11 cases (4.8%), while B-cell NHL was found in 214 cases (95%). Diffuse large B-cell lymphoma was the predominant type (n=156; 69.3%). Among T-cell lymphomas, anaplastic T-cell lymphoma was the most common subtype (n=6; 2.6%) followed by angioimmunoblastic T-cell lymphoma (n=2; 0.8%) and T-cell lymphoblastic lymphoma (n=1; 0.4%). For classical HL, mixed cellularity was the predominant type (n=38; 50%) followed by nodular sclerosis (n=31; 40.8%), lymphocyte depleted (n=5; 6.6%), and lymphocyte rich (n=2; 2.6%). Stage IV was present in 21 HL cases (27.6%), and stage IV was seen in 67 NHL cases (29.7%) at the time of diagnosis. Most HL and NHL patients were male. Most HL cases presented in the younger age group (aged 15 to 35 years), while the largest group of NHL patients were aged 56 to 75 years. Conclusion Our population has a broad spectrum of lymphoma and its subtypes. NHL is more common than HL, and the frequency of B-cell NHL is higher than that of T-cell NHL. Approximately one-third of the patients presented in stage IV at the time of diagnosis. An awareness of clinicopathological characteristics of lymphoma in our setup would aid in diagnosis, formulating standard management plans, and prevention strategies for optimal patient outcomes.Entities:
Keywords: b-cell; hodgkin's disease; lymphoma; neoplasms; non-hodgkin lymphoma; t-cell
Year: 2022 PMID: 35784957 PMCID: PMC9249068 DOI: 10.7759/cureus.25620
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Figure 1Types of lymphoma
Figure 2Gender distribution in lymphoma patients
Figure 3Age statistics in lymphoma patients
Figure 4Frequency of subtypes of Hodgkin's lymphoma
Figure 5Distribution of non-Hodgkin's lymphoma
DLBCL, diffuse large B-cell lymphoma; MALT, mucosa-associated lymphoid tissue; ALK, anaplastic lymphoma kinase positive.
Prevalence of stage IV disease in Hodgkin’s lymphoma
| Stage IV | ||||
| Absent | Present | |||
| Hodgkin lymphoma | N | Percentage | N | Percentage |
| Mixed cellularity | 26 | 47.3% | 12 | 57.1% |
| Nodular sclerosis | 24 | 43.6% | 7 | 33.3% |
| Lymphocyte depleted | 3 | 5.5% | 2 | 9.5% |
| Lymphocyte rich | 2 | 3.6% | 0 | 0.0% |
Prevalence of stage IV disease in non-Hodgkin’s lymphoma
DLBCL, diffuse large B-cell lymphoma; MALT, mucosa-associated lymphoid tissue; ALK, anaplastic lymphoma kinase positive.
| Stage IV | ||||
| Absent | Present | |||
| Non-Hodgkin lymphoma | N | Percentage | N | Percentage |
| DLBCL | 110 | 69.6% | 46 | 68.7% |
| Follicular lymphoma | 13 | 8.2% | 6 | 9.0% |
| Mantle cell lymphoma | 8 | 5.1% | 3 | 4.5% |
| Small lymphocytic lymphoma | 8 | 5.1% | 6 | 9.0% |
| MALT lymphoma | 3 | 1.9% | 2 | 3.0% |
| Marginal zone lymphoma | 3 | 1.9% | 0 | 0.0% |
| ALK-positive anaplastic large cell lymphoma | 4 | 2.5% | 1 | 1.5% |
| ALK-negative anaplastic large cell lymphoma | 1 | 0.6% | 0 | 0.0% |
| Angioimmunoblastic T-cell lymphoma | 2 | 1.3% | 0 | 0.0% |
| Plasmablastic lymphoma | 1 | 0.6% | 0 | 0.0% |
| Cutaneous T-cell lymphoma | 1 | 0.6% | 1 | 1.5% |
| Burkitt's lymphoma | 2 | 1.3% | 1 | 1.5% |
| B lymphoblastic lymphoma | 1 | 0.6% | 1 | 1.5% |
| T lymphoblastic lymphoma | 1 | 0.6% | 0 | 0.0% |